Core Viewpoint - The article emphasizes the growing interest in the development of new carbon sources and biotechnological conversion, particularly in the context of industrial carbon-rich gas fermentation for fuel ethanol production. Group 1: Industrial Carbon-Rich Gas Fermentation Technology - The anaerobic microorganisms utilize the Wood-Ljungdahl pathway to absorb and fix CO and CO2 from industrial carbon-rich gases, synthesizing products like acetic acid and ethanol. The main advantages of this technology include low energy consumption, high safety, strong substrate specificity of enzymes, and high adaptability to raw material gas composition [3][4]. - The overall efficient conversion process is identified as a core challenge for scaling up industrial applications, closely related to stable gas supply, efficient strain development, fermentation process optimization, and market prospects [3][4]. Group 2: Progress of Industrial Carbon-Rich Gas Biomanufacturing Enterprises - Companies like LanzaTech and Jupeng Bio have established multiple industrial fermentation facilities. LanzaTech, a leader in gas fermentation, has formed a joint venture with Shougang Group, operating four production bases in China with an annual capacity of 210,000 tons of fuel ethanol and 23,200 tons of microbial protein by 2025 [4][6]. - Jupeng Bio is noted for its unique full-chain technology from biomass gasification to gas fermentation, with a demonstration plant completed in 2021 and a large-scale commercial facility under construction in Inner Mongolia [6][8]. - Other companies such as Synata Bio and Jitai Laibo Bio are rapidly developing in this field, with Synata Bio's 10-ton gas fermentation facility already completed [7][8]. Group 3: Challenges in Industrialization - The technology faces four main challenges: 1. **Gas Source Stability**: Variability in gas composition and quantity from upstream industries can affect the growth and metabolism of acetic acid-producing bacteria, potentially leading to fermentation system failure [9]. 2. **Process Control Precision**: There is a need for precise control technologies for gas inflow and product composition, as current methods for monitoring CO levels are inadequate [10][11]. 3. **Reactor Design**: Existing reactors often have low capacity and high production costs, necessitating the development of larger reactors while considering efficiency and operational costs [16][17]. 4. **Separation and Purification**: The low concentration of ethanol in fermentation necessitates the development of new separation technologies to reduce energy consumption during purification [20][22]. Group 4: Upcoming Industry Events - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on new carbon source exploration and bioconversion opportunities [23][28].

Core Viewpoint - Meihua Biotech has successfully completed the acquisition of the amino acid business and assets from Concord Fermentation, enhancing its product and business structure in the synthetic biology sector [1]. Group 1: Acquisition Details - The acquisition was finalized on July 1, 2025, with a transaction price of approximately 16.8 billion Japanese yen, equivalent to about 833 million RMB [1]. - The final transaction price was adjusted based on the cash reserves and working capital of the target assets at the time of closing, which included an estimated cash amount of 11.3 billion Japanese yen (approximately 560 million RMB) [1]. - Concord Fermentation is recognized as a leader in biotechnology and fermentation, focusing on high-quality amino acids and other synthetic biology products [1]. Group 2: Business Expansion - The acquisition allows Meihua Biotech to diversify its product offerings by adding various new amino acid products and strains, enhancing its fermentation and refinement capabilities for high-value pharmaceutical amino acids [1]. - The company will also gain production capabilities and intellectual property for three types of Human Milk Oligosaccharides (HMO) through the integration of a precision fermentation platform [1]. - The acquisition supports the company's strategy to expand its industrial footprint internationally by acquiring multiple domestic and foreign operational entities [1]. Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion RMB, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2]. - The growth in this segment is attributed to the rise in both volume and price of lysine, as well as increased sales of threonine, positioning it as a potential new growth driver for the company [2].

Core Viewpoint - The annual report of Bloomage Biotechnology Corporation Limited for 2024 highlights a significant decline in revenue and net profit, attributed to management changes, increased operational costs, and a decrease in income from skin science innovation transformation business [1][3][6]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 5.37 billion yuan, a decrease of 11.61% compared to the previous year [3]. - The net profit attributable to shareholders was approximately 174 million yuan, reflecting a 70.59% decline year-on-year [3]. - The net profit after deducting non-recurring gains and losses was about 107 million yuan, down 78.13% from the previous year [3]. - The basic earnings per share decreased to 0.36 yuan, a drop of 70.73% [3]. Business Performance and Strategic Initiatives - The company is undergoing a strategic upgrade, focusing on synthetic biology and cell biology to enhance its product offerings and operational efficiency [6][12]. - Management changes and restructuring efforts have incurred costs exceeding 70 million yuan, impacting short-term profitability but aimed at long-term growth [6][12]. - The company has initiated over 30 transformation projects to improve operational management and efficiency [16][20]. Revenue Breakdown - The raw materials business generated approximately 1.24 billion yuan, a year-on-year increase of 9.47%, accounting for 23.06% of total revenue [7]. - The skin science innovation transformation business reported revenue of approximately 2.57 billion yuan, a decline of 31.62%, making up 47.92% of total revenue [11][12]. - The medical terminal business achieved revenue of approximately 1.07 billion yuan, a growth of 43.57% [10]. Research and Development - The company invested 8.68% of its revenue in R&D, up from 7.35% the previous year, focusing on innovative products in the fields of regenerative medicine and nutritional science [3][5]. - New product launches included several innovative raw materials and medical products, enhancing the company's product portfolio [18][19]. ESG and Sustainability Efforts - The company has committed to sustainable development practices, becoming a member of the UN Global Compact and improving its ESG ratings [22]. - Initiatives include optimizing the ESG management system and focusing on green, low-carbon production [22].

证券代码：688363 证券简称：华熙生物 公告编号：2025-024 华熙生物科技股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司" "华熙生物"）于近日收到 上海证券交易所科创板公司管理部下发的《关于华熙生物科技股份有限公司 （上证科创公函【2025】0245 号，以 下简称" 《问询函》"）。公司对上述《问询函》提到的问题高度重视，公司与致 同会计师事务所（特殊普通合伙） （以下简称"年审会计师"或"会计师"）对 《问询函》所涉及的问题进行了审慎核查，现就相关问题回复如下： 问题一、关于公司主营业务和经营业绩。年报披露，2024 年度，公司营 业收入 53.71 亿元，同比下滑 11.61%，其中功能性护肤品业务收入同比下滑 肤品业务收入下滑、期间费用增加及资产减值损失等因素影响，公司实现净利 润 1.74 亿元，同比下滑 70.59%。公司近年从产品、渠道、组织、品牌等方面 进行调整以夯实业务基础，20 ...

生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （现场展示科技成果推介墙）， 公开征集100个从0—1—100的合成生物和生物制造领域创新成果 和项目 ，于现场展示、对接。 欢迎科研院所、企业报名！ 往期现场： 03 大会日程 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 ...

将酵母细胞进行基因工程改造，改变其代谢通路之后，放入百升级的发酵罐。经过三五天的发酵周期， 从发酵液中分离出目标代谢产物，其产量可代替5万亩青蒿种植的提取量。自2013年起，利用酵母商业 化生产的青蒿素，正为发展中国家数以亿万计的疟疾患者作出贡献。 这是合成生物学早期最具代表性的案例。基因编辑技术带来了第三次生物学革命，被称作"上帝的手术 刀"，也是合成生物学最核心的工具。作为北京国际科技创新中心的重要组成部分，北京昌平区聚集的 120余家合成生物制造企业正在将这把"手术刀"打磨得愈发锋利，也将推动合成生物产业成为新质生产 力的关键引擎。 技术突破，为漫长选育与驯化进程"抄近道" 专注于基因编辑生物育种赛道的北京齐禾生物科技有限公司（以下简称齐禾生物），是昌平区合成生物 制造产业的代表企业之一。 "通过对基因的精准调控和改变，大豆中的油酸含量从20%多提高到了80%以上。"齐禾生物首席执行官 张蓓告诉记者，齐禾生物目前已实现对多种粮食及经济作物农艺性状和品质性状的精准改良，并在过去 四年中获得了五张植物基因编辑安全证书。 除了高油酸大豆，抗白粉病高产小麦、高产大豆、耐除草剂小麦及品质改良水稻等新品种，也通过一 ...

Investment and Expansion - Angel Yeast plans to invest CNY 502 million to establish a biomanufacturing center, which will include a seven-story building with a total area of 27,687.65 square meters and an underground parking area for 297 vehicles [1][3] - The project is expected to enhance Angel Yeast's technological innovation capabilities in biomanufacturing, thereby strengthening its profitability and competitive edge [1][3] - Zhou Liufu, a jewelry company, successfully listed on the Hong Kong Stock Exchange, opening with a more than 10% increase and reaching a market capitalization of over HKD 10.5 billion [5] - Zhou Liufu's online sales are projected to grow at a compound annual growth rate of 46.1% from 2022 to 2024, with online sales expected to account for 40% of total revenue by 2024 [5] Market Position and Strategy - Ying Tong Holdings, the largest perfume brand management company in China, officially listed on the Hong Kong Stock Exchange, marking its strong market position [7] - The company is recognized as the third-largest perfume group in the comprehensive markets of mainland China, Hong Kong, and Macau, indicating its robust capability to enter the stock market [7] - Danone's acquisition of The Akkermansia Company aims to strengthen its investment in gut health and next-generation biological research, enhancing its core competitiveness in this field [11][13] - Dazzle Fashion Group announced the closure of all offline stores for its men's brand RAZZLE by August 31, 2025, focusing resources on its core mid-to-high-end women's wear business [16] Retail and Brand Development - HotMaxx's new store format, HotMaxx Super Warehouse, has opened in Beijing, featuring seven product zones while maintaining a low-price strategy [10] - Uniqlo plans to open its first store in southern India in Bangalore, marking a significant expansion into the southern market [18] Leadership Changes - The former business general manager of Kraft Heinz in China has joined Mondelēz as the head of the frozen cake team for Greater China, indicating a strategic focus on growth in the frozen baking sector [20] - Alibaba Group has streamlined its partner organization from 26 to 17 members, emphasizing a focus on frontline business leaders [22] - Anna Wintour announced her resignation as editor-in-chief of American Vogue while retaining her role as global editorial director, reflecting changes in the fashion media landscape [25]

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 欢迎科研院所、企业报名！ 往期现场： 03 大会日程 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioC ...

#SynBio团队 | 以色列魏茨曼科学研究院 【SynBioCon】 获 悉 ， 以色列魏茨曼科学研究院科学家在新一期《自然》杂志发表文章称：他们利用基于酶工 作原理的计算机新算法设计出高效人工合成酶。这种新型酶不仅能催化天然蛋白质无法完成的化学反应， 其效率 更达到人工智能（AI）设计酶的100倍 ，标志着"按需定制"高效酶的新阶段即将来临。 传统计算机算法辅助设计的酶往往效率低下，需要耗费大量时间进行实验室优化。为突破这一瓶颈，研究团队独 辟蹊径，选择"肯普消除"（一种涉及从特定底物碳原子上移除质子的非天然化学反应）作为验证案例。 过去十年，AI蛋白质设计大行其道，但其工作机制主要模仿现有酶。相比之下，新算法的工作机制是基于物理原 理来构建酶。研究团队表示，AI在处理某些蛋白质设计时确实无可替代，但对于复杂催化反应仍力不从心。未来 需要将两种方法优势互补，才能设计出更完美的酶。 通过算法设计的一种酶（白色）将底物（红色、黄色和蓝色）包裹于其活性位点内。图片来源：《自然》网站 ▌ 参考信息： 本文部分 素 材 来 自全网 。由 作 者重新 编写，系作者个人观点，本平台发布仅为了传达一种不同观点，不代表对该 ...

近年来，生物制造已作为多数国家提升经济竞争力的着力点，也是我国继绿色制造、智能制造后，推进制造强国建设的又一重要抓手。同时，各地政府 地区通过结合自身优势力争实现合成生物"研发－转化－产业—集群"协同发展，发挥新质生产力 作用。 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2 025 ) 。大会 聚焦" 1+4 " ： AI+生 物智造 这一大热门赛道； 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ，邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ； 哪些革新技术和产品将给生物制造产业带来持续的生命力 ； 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主办单位： 宁波德泰中研信息科技有限公司（ DT 新材料） 协办 单位： 宁波酶赛生物工程有限公司 二、大会亮点 三、大会日程 亮点一 ： 大会论坛、闭门活动洞察"十五五"生物制造发展趋势！探索新产品、新技术、新落地、 新合作！ 亮点二： 青年创新技术与价值分享、人才对接与合作！ 亮 ...